RESUMO
BACKGROUND AND OBJECTIVE: Severity assessment is made at the time of the initial clinical presentation in patients with community-acquired pneumonia (CAP). It is unclear how the gap between time of presentation and duration of symptoms onset may impact clinical outcomes. Here we evaluate the association of prolonged onset of symptoms (POS) and the impact on clinical outcomes among hospitalized patients with CAP. METHODS: This was a prospective, multicentre study of CAP in Spain. The primary outcomes were the clinical factors associated with POS defined as days from symptoms onset to pneumonia diagnosis >7 days. The secondary outcomes were intensive care unit (ICU) admission, the presence of suppurative complications, septic shock and 30-day mortality. RESULTS: We enrolled 1038 patients diagnosed of CAP: 152 (14.6%) patients had a POS. In multivariate analysis, the presence of prior corticosteroid therapy, alcohol abuse, prior antibiotic therapy, and confusion, urea, respiratory rate, blood pressure and age 65 years or older score 0-1 was independently associated with POS. Patients with POS had a higher incidence of suppurative complications, but not of 30-day mortality when compared with a shorter onset of symptoms. CONCLUSIONS: Approximately 15% of patients diagnosed with CAP had POS. Risk factors associated with POS were previous corticosteroids and antibiotic therapy, alcoholism and less severe pneumonia. POS was associated with a higher rate of suppurative complications and less need for ICU admission.
Assuntos
Diagnóstico Tardio , Infecções por Bactérias Gram-Negativas/diagnóstico , Infecções por Bactérias Gram-Positivas/diagnóstico , Pneumonia Bacteriana/diagnóstico , Pneumonia Viral/diagnóstico , Tempo para o Tratamento , Idoso , Antibacterianos/uso terapêutico , Estudos de Coortes , Infecções Comunitárias Adquiridas , Feminino , Infecções por Bactérias Gram-Negativas/complicações , Infecções por Bactérias Gram-Negativas/terapia , Infecções por Bactérias Gram-Positivas/complicações , Infecções por Bactérias Gram-Positivas/terapia , Hospitalização , Humanos , Legionella pneumophila , Masculino , Pessoa de Meia-Idade , Mycoplasma pneumoniae , Pneumonia Bacteriana/complicações , Pneumonia Bacteriana/terapia , Pneumonia Viral/complicações , Pneumonia Viral/terapia , Prognóstico , Espanha , Streptococcus pneumoniaeRESUMO
INTRODUCTION: There is currently no universally accepted definition of asthma-COPD overlap (ACO). OBJECTIVE: To compare the prevalence of ACO in patients with asthma or COPD, and to assess their clinical characteristics and the capacity of the different definitions to predict the risk of exacerbation. METHOD: Prospective observational study with a 12-month follow-up in an asthma cohort and a COPD cohort. Four diagnostic criteria were compared: A) the Spanish 2012 consensus; B) the 2016 international consensus; C) the 2017 consensus between the Spanish COPD guidelines (GesEPOC) and GEMA asthma guidelines; and D) the single criterion of ≥300eosinophils/µL, proposed by GOLD 2019. The risk of exacerbations was evaluated in each group. RESULTS: A total of 345 patients were included, 233 (67.5%) with COPD and 112 (32.5%) with asthma, aged 63±14 years, 70.4% men. Fifteen (4.3%) patients met the criteria for ACO according to the criteria described under A above; 30 (8.7%) with the criteria of B; 118 (34.2%) with the criteria of C; and 97 (28.1%), with the D criterion. The ACO-COPD subtype were older, had worse lung function, and an increased risk of exacerbation compared with the ACO-asthma group. Of all the definitions evaluated, those which distinguished a higher risk of exacerbations were the GesEPOC-GEMA consensus and the GOLD proposal. CONCLUSIONS: The prevalence of ACO varies enormously depending on the diagnostic criteria used. The ACO population is heterogeneous, and the ACO-COPD subtype is very different from the ACO-asthma subtype. The definitions that include eosinophilia identify ACO patients with a greater risk of exacerbation.
Assuntos
Asma , Eosinofilia , Doença Pulmonar Obstrutiva Crônica , Asma/diagnóstico , Estudos de Coortes , Feminino , Humanos , Masculino , Prevalência , Doença Pulmonar Obstrutiva Crônica/diagnósticoRESUMO
OBJECTIVES: To compare clinical outcomes and costs between two administration strategies of omalizumab treatment. METHOD: We evaluated two cohorts of patients with uncontrolled severe asthma over a 1-year period. Patients received the treatment in the primary care center in Hospital A and conventional hospital administration in Hospital B. RESULTS: We studied 130 patients, 86 in Hospital A and 44 in Hospital B, 30 men (24%) and 100 women (76%), age 50 ± 15 years, FEV1% 67 ± 22%, body mass index (BMI) 28 ± 6 kg/m(2), 639 ± 747 UI IgE/mL, followed for 24 ± 11 months (12-45), Asthma Control Test (ACT) score 12 ± 4 and Asthma Control Questionnaire (ACQ) 3 ± 2. There were no significant pretreatment differences between the groups in hospital admissions and emergency room visits in the previous year, nor in proportion of patients receiving oral steroids. Evaluations were performed at baseline and after 12 months of treatment, revealing significant differences in ACT (P<0.001), ACQ (P<0.001), improvement in FEV1% (P<0.001), reduction in total admissions (P<0.001), days of hospitalization (P<0.001), emergency room visits (P<0.001), cycles and doses of oral steroids (P<0.001) compared to the previous year. Hospitalization costs, emergency room visits, unscheduled visits to primary care and to the pulmonologist were significantly reduced in each hospital and on the whole, but administration and travel costs were 35% lower in the ambulatory strategy adopted in Hospital A. CONCLUSION: The administration of omalizumab in ambulatory health centers achieved the same clinical results as a hospital administration strategy, but with lower costs.
Assuntos
Assistência Ambulatorial/economia , Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Custos e Análise de Custo , Hospitalização/economia , Omalizumab/economia , Omalizumab/uso terapêutico , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Índice de Gravidade de DoençaRESUMO
Amyloidosis is a systemic disease caused by abnormal deposition of amyloid material that is detected with Congo red staining and is difficult to diagnose. Involvement of the tracheobronchial tree is rare and is a challenge for pulmonologists because of the wide differential diagnosis of this disease. We present two cases where tracheobronchial affectation has been observed: in one of them as a primary disease, and in another as secondary affectation. The use of bronchoscopic techniques is essential for the diagnosis of tracheobronchial involvement. In the absence of an effective drug therapy, local management of this disease with endoscopic techniques for bronchial repermeabilization is able to provide clinical improvement and expand the treatment options and prognosis in this disease.
Assuntos
Amiloidose/cirurgia , Broncopatias/cirurgia , Broncoscopia/métodos , Doenças da Traqueia/cirurgia , Obstrução das Vias Respiratórias/etiologia , Obstrução das Vias Respiratórias/cirurgia , Amiloidose/complicações , Amiloidose/diagnóstico , Amiloidose/tratamento farmacológico , Amiloidose/patologia , Biópsia , Birrefringência , Medula Óssea/patologia , Broncopatias/diagnóstico , Broncopatias/tratamento farmacológico , Broncopatias/patologia , Neoplasias Brônquicas/diagnóstico , Corantes , Terapia Combinada , Vermelho Congo , Diagnóstico Diferencial , Feminino , Hemoptise/etiologia , Humanos , Terapia a Laser , Pulmão/patologia , Neoplasias Pulmonares/diagnóstico , Masculino , Melfalan/uso terapêutico , Pessoa de Meia-Idade , Prednisona/uso terapêutico , Doenças da Traqueia/diagnóstico , Doenças da Traqueia/tratamento farmacológico , Doenças da Traqueia/patologiaRESUMO
INTRODUCTION: Fournier's gangrene is a serious and potentially lethal rare infection of perineal and external genital that must be treated as a medical and surgical emergency. The aim of this study is to share our experience over the last 10 years in the management of this disease. PATIENTS AND METHOD: We carried out a descriptive and retrospective chart review of patients diagnosed and treated for this pathology in our Hospital over the last 10 years. The patient age, sex, risk factors, urgent laboratory investigations, presenting symptoms, duration of hospital stay, microbiological findings, and number of debridements were recorded. RESULTS: Six patients had this pathology, all males, with a mean age of 58.5 years. Half of them (50%) showed predisposing factors, but none of them showed a clear aetiology. The initial symptomatology was perineal or perianal phlegmon-abscess with a torpid evolution and gangrene. The treatment was intravenous antibiotics and debridement, which was repeated in 4 patients. The most commonly isolated microorganism was Escherichia coli followed by Acinetobacter and Bacteroides. The mean hospital stay was 32 days. There were no deaths recorded in this study. CONCLUSIONS: Fournier's gangrene is a serious disease that occurs in patients with risk factors. Early surgical treatment and broad-spectrum antibiotics are important.